TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-Center, Open-Label, Randomized Study to Assess the Safety and Contraceptive Efficacy of Two Doses ( in vitro12 µg/24h and 16 µg/24h) of the Ultra Low Dose Levonorgestrel Contraceptive Intrauterine Systems (LCS) for a Maximum of 3 Years in Women 18 to 35 Years of Age and an Extension Phase of the 16µg/24h Dose Group (LCS16 Arm) up to 5 Years
Brief Summary: This is a study on a new low dose levonorgestrel contraceptive intrauterine systems (LCS). The purpose of the study is to investigate which of the 2 administered doses is the lowest effective intrauterine dose of Levonorgestrel (LNG) administered via the LCS for contraception during 3 years. The study was amended: the LCS16 arm will be extended up to 5 years


Options:
A: Arm Label: Normal Weight group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose formulation, Drug: High dose formulation | Arm Label: Obese group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose formulation, Drug: High dose formulation | Intervention Type: DRUG; Name: Low dose formulation; Assigned to Arm(s): Normal Weight group, Obese group | Intervention Type: DRUG; Name: High dose formulation; Assigned to Arm(s): Normal Weight group, Obese group
B: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A
C: Arm Label: LCS12; Type: EXPERIMENTAL; Interventions: Drug: LCS12 | Arm Label: LCS16; Type: EXPERIMENTAL; Interventions: Drug: LCS16 | Intervention Type: DRUG; Name: LCS12; Assigned to Arm(s): LCS12 | Intervention Type: DRUG; Name: LCS16; Assigned to Arm(s): LCS16
D: Arm Label: AG200-15 (cycles 1-13); Type: EXPERIMENTAL; Interventions: Drug: AG200-15 (cycles 1-13) | Arm Label: Lessina crossover to AG200-15; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lessina crossover to AG200-15 | Intervention Type: DRUG; Name: AG200-15 (cycles 1-13); Assigned to Arm(s): AG200-15 (cycles 1-13) | Intervention Type: DRUG; Name: Lessina crossover to AG200-15; Assigned to Arm(s): Lessina crossover to AG200-15

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treating Childhood Obesity With Family Lifestyle Change
Brief Summary: The purpose of this study is to determine whether an intense family-centered program to help children, 4 to 7 years old, control their weight is more effective than the advise and referrals their health provider gives in the primary care office.


Options:
A: Arm Label: Team PLAY Group; Type: EXPERIMENTAL; Interventions: Behavioral: Team PLAY | Arm Label: Standard Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Team PLAY; Assigned to Arm(s): Team PLAY Group
B: Arm Label: Intervention- Lifestyle family based; Type: EXPERIMENTAL; Interventions: Behavioral: family based lifestyle and behavioral counseling | Arm Label: Information control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: counseling focused on the child | Intervention Type: BEHAVIORAL; Name: family based lifestyle and behavioral counseling; Assigned to Arm(s): Intervention- Lifestyle family based | Intervention Type: BEHAVIORAL; Name: counseling focused on the child; Assigned to Arm(s): Information control
C: Intervention Type: BEHAVIORAL; Name: To change structure and roles of primary care teams to optimize prevention of obesity; Assigned to Arm(s): N/A
D: Arm Label: Standard Care with Education Materials; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Care | Arm Label: Moderate Dose Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Moderate Dose Motivational Interviewing | Arm Label: Higher Dose Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Higher Dose Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard Care with Education Materials | Intervention Type: BEHAVIORAL; Name: Moderate Dose Motivational Interviewing; Assigned to Arm(s): Moderate Dose Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Higher Dose Motivational Interviewing; Assigned to Arm(s): Higher Dose Motivational Interviewing

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of a School Based Hand Sanitizer Program on Asthma
Brief Summary: Asthma is a common, serious illness among children in the United States. Improving hand cleanliness and hygiene may prevent the spread of viruses that can cause asthma exacerbations. This study will evaluate the effectiveness of a school-based hand sanitizer program at reducing the frequency of exacerbations in children with asthma.


Options:
A: Arm Label: Two Step Hand-Hygiene; Type: EXPERIMENTAL; Interventions: Other: Active Hand Sanitizer | Arm Label: Usual Care Hand Hygiene; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Active Hand Sanitizer; Assigned to Arm(s): Two Step Hand-Hygiene
B: Arm Label: Omalizumab (Xolair) + Conventional Therapy; Type: EXPERIMENTAL; Interventions: Biological: omalizumab | Arm Label: Placebo + Conventional Therapy; Type: PLACEBO_COMPARATOR; Interventions: Biological: omalizumab placebo | Intervention Type: BIOLOGICAL; Name: omalizumab; Assigned to Arm(s): Omalizumab (Xolair) + Conventional Therapy | Intervention Type: BIOLOGICAL; Name: omalizumab placebo; Assigned to Arm(s): Placebo + Conventional Therapy
C: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Biological: Omalizumab, Biological: Placebo fluticasone | Arm Label: Inhaled Corticosteroid Boost Therapy (ICS); Type: EXPERIMENTAL; Interventions: Drug: Inhaled Corticosteroid Boost Therapy (ICS), Biological: Placebo omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo omalizumab, Biological: Placebo fluticasone | Intervention Type: BIOLOGICAL; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Inhaled Corticosteroid Boost Therapy (ICS); Assigned to Arm(s): Inhaled Corticosteroid Boost Therapy (ICS) | Intervention Type: BIOLOGICAL; Name: Placebo omalizumab; Assigned to Arm(s): Inhaled Corticosteroid Boost Therapy (ICS), Placebo | Intervention Type: BIOLOGICAL; Name: Placebo fluticasone; Assigned to Arm(s): Omalizumab, Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: montelukast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Randomised, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Comparison Over 24 Weeks of Three Doses (50µg, 100µg, 200µg) of BEA 2180 BR to Tiotropium 5µg, Delivered by the Respimat Inhaler and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The primary objective of this study is to compare the bronchodilator efficacy of three doses (50 µg, 100 µg and 200 µg) of BEA 2180 delivered by the Respimat® once daily to placebo and tiotropium bromide delivered by the Respimat® in patients with COPD. Additional objectives include comparing the effects on dyspnea and health status.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Budesonide/formoterol (Symbicort Turbuhaler) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol (Oxis Turbuhaler) | Intervention Type: DRUG; Name: Budesonide/formoterol (Symbicort Turbuhaler); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Formoterol (Oxis Turbuhaler); Assigned to Arm(s): 2
B: Arm Label: Tiotropium; Type: OTHER; Interventions: Drug: Tiotropium | Arm Label: Placebo; Type: OTHER; Interventions: Device: Respimat | Intervention Type: DEVICE; Name: Respimat; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium
C: Arm Label: FF/GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF Inhalation Powder | Arm Label: GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FF/GW642444 Inhalation Pwdr; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Powder, FF/GW642444 Inhalation Pwdr | Intervention Type: DRUG; Name: FF Inhalation Powder; Assigned to Arm(s): FF Inhalation Powder | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 Inhalation Powder | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: BEA 2180 BR low dose; Type: EXPERIMENTAL; Interventions: Drug: BEA 2180 BR | Arm Label: BEA 2180 BR medium dose; Type: EXPERIMENTAL; Interventions: Drug: BEA 2180 BR | Arm Label: BEA 2180 BR high dose; Type: EXPERIMENTAL; Interventions: Drug: BEA 2180 BR | Arm Label: Tiotropium Bromide; Type: EXPERIMENTAL; Interventions: Drug: Tiotropium Bromide | Intervention Type: DRUG; Name: BEA 2180 BR; Assigned to Arm(s): BEA 2180 BR high dose, BEA 2180 BR low dose, BEA 2180 BR medium dose | Intervention Type: DRUG; Name: Tiotropium Bromide; Assigned to Arm(s): Tiotropium Bromide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Multicenter, Randomized, Double-blind, Parallel-group, Active-control, Dose-ranging Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subject Undergoing Hemorrhoidectomy
Brief Summary: Phase 2 study to evaluate three dose levels of SKY0402 compared with 75 mg of bupivacaine HCl.


Options:
A: Arm Label: SKY0402 high dose; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Arm Label: SKY0402 middle dose; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Arm Label: SKY0402 low dose; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Arm Label: Bupivacaine HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine HCl | Intervention Type: DRUG; Name: SKY0402; Assigned to Arm(s): SKY0402 high dose, SKY0402 low dose, SKY0402 middle dose | Intervention Type: DRUG; Name: Bupivacaine HCl; Assigned to Arm(s): Bupivacaine HCl
B: Arm Label: IV morphine sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV morphine sulfate | Arm Label: EXPAREL; Type: EXPERIMENTAL; Interventions: Drug: EXPAREL (bupivacaine liposome injectable suspension) | Intervention Type: DRUG; Name: IV morphine sulfate; Assigned to Arm(s): IV morphine sulfate | Intervention Type: DRUG; Name: EXPAREL (bupivacaine liposome injectable suspension); Assigned to Arm(s): EXPAREL
C: Arm Label: Bupivacaine HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine HCl | Arm Label: SKY0402; Type: OTHER; Interventions: Drug: SKY0402 | Intervention Type: DRUG; Name: Bupivacaine HCl; Assigned to Arm(s): Bupivacaine HCl | Intervention Type: DRUG; Name: SKY0402; Assigned to Arm(s): SKY0402
D: Arm Label: IV Morphine Sulfate or Sponsor-approved Equivalent; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV morphine sulfate or Sponsor-approved equivalent | Arm Label: EXPAREL; Type: EXPERIMENTAL; Interventions: Drug: EXPAREL | Intervention Type: DRUG; Name: IV morphine sulfate or Sponsor-approved equivalent; Assigned to Arm(s): IV Morphine Sulfate or Sponsor-approved Equivalent | Intervention Type: DRUG; Name: EXPAREL; Assigned to Arm(s): EXPAREL

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Study to Determine the Efficacy and Safety of Pravastatin 80 mg Administered Once Daily to Hypercholesterolemic Subjects With Chronic, Well Compensated Liver Disease
Brief Summary: To determine in hypercholesterolemic subjects with chronic, well-compensated liver disease, the percent change from baseline to Week 12 in serum LDL-C of pravastatin 80 mg compared to placebo.


Options:
A: Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Pravastatin; Assigned to Arm(s): N/A
C: Arm Label: Fosinopril + Pravastatin; Type: EXPERIMENTAL; Interventions: Drug: Fosinopril, Drug: Pravastatin | Arm Label: Fosinopril + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fosinopril, Drug: Pravastatin Placebo | Arm Label: Pravastatin + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pravastatin, Drug: Fosinopril Placebo | Arm Label: Double Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fosinopril Placebo, Drug: Pravastatin Placebo | Intervention Type: DRUG; Name: Fosinopril; Assigned to Arm(s): Fosinopril + Placebo, Fosinopril + Pravastatin | Intervention Type: DRUG; Name: Pravastatin; Assigned to Arm(s): Fosinopril + Pravastatin, Pravastatin + Placebo | Intervention Type: DRUG; Name: Fosinopril Placebo; Assigned to Arm(s): Double Placebo, Pravastatin + Placebo | Intervention Type: DRUG; Name: Pravastatin Placebo; Assigned to Arm(s): Double Placebo, Fosinopril + Placebo
D: Arm Label: Lisinopril; Type: EXPERIMENTAL; Interventions: Drug: Lisinopril | Arm Label: Lisinopril Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lisinopril | Arm Label: Pravastatin; Type: EXPERIMENTAL; Interventions: Drug: Pravastatin | Arm Label: Pravastatin placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pravastatin | Intervention Type: DRUG; Name: Pravastatin; Assigned to Arm(s): Pravastatin, Pravastatin placebo | Intervention Type: DRUG; Name: Lisinopril; Assigned to Arm(s): Lisinopril, Lisinopril Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Organisational Changes to Promote Smoking Cessation
Brief Summary: The Department of Family Practice at Michigan State University partnered with BCBSM with a grant from the Robert Wood Johnson Foundation to recruit primary care practices for a 3 year study designed to assess smoking cessation referral rates by primary care physicians in Michigan.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation | Arm Label: Simultaneous; Type: EXPERIMENTAL; Interventions: Behavioral: Weight gain prevention and smoking cessation | Arm Label: Sequential; Type: EXPERIMENTAL; Interventions: Behavioral: Weight gain prevention and smoking cessation | Intervention Type: BEHAVIORAL; Name: Weight gain prevention and smoking cessation; Assigned to Arm(s): Sequential, Simultaneous | Intervention Type: BEHAVIORAL; Name: Smoking cessation; Assigned to Arm(s): Control
B: Arm Label: Proactive group; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Behavioral: Tobacco Quit Line Program | Arm Label: Reactive group; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Behavioral: Tobacco Quit Line Program | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Proactive group, Reactive group | Intervention Type: BEHAVIORAL; Name: Tobacco Quit Line Program; Assigned to Arm(s): Proactive group, Reactive group
C: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A
D: Arm Label: 2; Type: NO_INTERVENTION; Interventions: Behavioral: Feeback group | Intervention Type: BEHAVIORAL; Name: Feeback group; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study was to estimate the safety and efficacy of titrated oral misoprostol compared with vaginal route for labor induction at term.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): 2
B: Arm Label: Oral Titrated Misoprostol Solution; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Vaginal Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Oral Titrated Misoprostol Solution | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Vaginal Misoprostol
C: Arm Label: conventional oral misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Arm Label: titrated oral misoprostol; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): conventional oral misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): titrated oral misoprostol
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study was to estimate the safety and efficacy of titrated oral misoprostol compared with vaginal route for labor induction at term.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 1, 2
B: Arm Label: conventional oral misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Arm Label: titrated oral misoprostol; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): conventional oral misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): titrated oral misoprostol
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): 2
D: Arm Label: Oxytocin augmentation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: Misoprostol augmentation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol augmentation | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin augmentation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study was to estimate the safety and efficacy of titrated oral misoprostol compared with vaginal route for labor induction at term.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 1, 2
B: Arm Label: misoprostol/placebo using buccal; Type: PLACEBO_COMPARATOR; Interventions: Drug: misoprostol/placebo | Arm Label: misoprostol/placebo using vaginal; Type: PLACEBO_COMPARATOR; Interventions: Drug: misoprostol/placebo | Intervention Type: DRUG; Name: misoprostol/placebo; Assigned to Arm(s): misoprostol/placebo using buccal, misoprostol/placebo using vaginal
C: Arm Label: conventional oral misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Arm Label: titrated oral misoprostol; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): conventional oral misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): titrated oral misoprostol
D: Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: dinoprostone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dinoprostone | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: DRUG; Name: Dinoprostone; Assigned to Arm(s): dinoprostone

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Postoperative Analgesia With Local Infiltration After Femoral Neck Fracture vs. Traditional Treatment of Pain With Opioids
Brief Summary: Reducing pain is an essential factor for early mobilization after osteosynthesis of femoral neck fractures. Systemic opioids have side effects that might obstruct mobilization and induce delirium and nausea. The investigators hypothesized that wound infiltration results in reduction in systemic opioid usage and pain relief without side effects.


Options:
A: Arm Label: Fascia iliaca block; Type: EXPERIMENTAL; Interventions: Procedure: Fascia iliaca block | Arm Label: Sham injection; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham injection | Intervention Type: PROCEDURE; Name: Fascia iliaca block; Assigned to Arm(s): Fascia iliaca block | Intervention Type: PROCEDURE; Name: Sham injection; Assigned to Arm(s): Sham injection
B: Arm Label: Standard Treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Continuous fascia iliaca block; Type: EXPERIMENTAL; Interventions: Procedure: Continuous fascia iliaca block, Drug: Ropivacaine | Intervention Type: PROCEDURE; Name: Continuous fascia iliaca block; Assigned to Arm(s): Continuous fascia iliaca block | Intervention Type: DRUG; Name: Ropivacaine; Assigned to Arm(s): Continuous fascia iliaca block
C: Arm Label: Exparel (Liposomal Bupivacaine); Type: EXPERIMENTAL; Interventions: Drug: Exparel | Arm Label: Saline Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride | Intervention Type: DRUG; Name: Exparel; Assigned to Arm(s): Exparel (Liposomal Bupivacaine) | Intervention Type: DRUG; Name: Sodium Chloride; Assigned to Arm(s): Saline Control
D: Arm Label: Ropivacaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ropivacaine | Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ropivacaine | Intervention Type: DRUG; Name: Ropivacaine; Assigned to Arm(s): Ropivacaine, Saline

Answer: D